| 1.435 0.015 (1.06%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.84  |
1-year : | 2.15 |
| Resists | First : | 1.58 |
Second : | 1.84 |
| Pivot price | 1.38 |
|||
| Supports | First : | 1.39 |
Second : | 1.27 |
| MAs | MA(5) : | 1.48 |
MA(20) : | 1.37 |
| MA(100) : | 1.36 |
MA(250) : | 1.39 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.7 |
D(3) : | 68.3 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 1.96 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MNOV ] has closed below upper band by 35.5%. Bollinger Bands are 131.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.44 - 1.45 | 1.45 - 1.46 |
| Low: | 1.41 - 1.42 | 1.42 - 1.43 |
| Close: | 1.42 - 1.43 | 1.43 - 1.45 |
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Wed, 26 Aug 2026
3 Promising Penny Stocks With Over $50M Market Cap - Sahm
Tue, 25 Aug 2026
MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Stock News, MNOV Share Price & Updates - Kalkine
Thu, 13 Aug 2026
MediciNova: Q2 Earnings Snapshot - KTVB
Thu, 23 Jul 2026
Price to sales forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 346 (K) |
| Shares Short P.Month | 205 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | 0 % |
| Operating Margin | -554.4 % |
| Return on Assets (ttm) | -16.5 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 240.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.01 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -6.84 |
| PEG Ratio | 0 |
| Price to Book value | 1.88 |
| Price to Sales | 76.73 |
| Price to Cash Flow | -7.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|